Anti-Her2 FluorAbody

About Sandia Biotech

Sandia Biotech is a private, early-stage biotech firm commercializing a novel fluorescent reagent platform called FluorAbodies. These reagents are single-chain variable fragments (ScFvs) genetically fused to fluorescent proteins, designed to overcome limitations of conventional antibody conjugates in research and diagnostics. The company appears to be in an early commercial phase, generating revenue through direct sales of its catalog products, with a primary focus on oncology biomarkers like HER2 and EphA2. Leadership includes co-founder and President Tony Pino, though the full team is not detailed on the public website.

Therapeutic Areas